Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults

Background Symptoms of attention-deficit hyperactivity disorder (ADHD) are known to persist into adulthood in the majority of cases. Aims To determine the prevalence of methylprienidate, dexamfetamine and atomoxetine prescribing and treatment discontinuation in adolescents and young adults. Method A descriptive cohort study using the UK General Practice Research Database included patients aged 15-21 years from 1999 to 2006 with a prescription for a study drug. Results Prevalence of prescribing averaged across all ages increased 6.23-fold over the study period. overall, prevalence decreased with age: in 2006, prevalence in males dropped 95% from 12.77 per 1000 in 15-year-olds to 0.64 per 1000 in 21-year-olds. A longitudinal analysis of a cohort of 44 patients aged 15 years in 1999 demonstrated that no patient received treatment after the age of 21 years. Conclusions The prevalence of prescribing by general practitioners to patients with ADHD drops significantly from age 15 to age 21 years. The fall in prescribing is greater than the reported age-related decrease in symptoms, raising the possibility that treatment is prematurely discontinued in some Young adults in whom symptoms persist.